Introduction The aim of the study was to build a model of first failure site–and lesion-specific
failure probability after definitive chemoradiotherapy for inoperable NSCLC. Methods We …

Background Stage III non-small cell lung cancer (NSCLC) is a highly heterogeneous stage
due to its subgroups (IIIA–IIIC) comprising both resectable and unresectable tumors …

Survival of lung cancer patients remains poor despite increasingly aggressive treatment.
Conventional staging has well-described limitations. 18F-FDG PET has been shown to …

PURPOSE: Dosimetric studies suggested several advantages to defining the radiotherapy
target by using positron-emission tomography (PET)/computed tomography (CT) compared …

BACKGROUND: The treatment of patients with nonsmall cell lung cancer (NSCLC) is
determined by the stage. We evaluated the accuracy of staging using integrated positron …

Objectives To investigate the role of PET in predicting the prognosis of resected stage IA non-
small cell lung cancer (NSCLC) and planning individualized therapeutic strategies. Methods …

Objective: To evaluate and compare positron emission tomography/computed tomography
(PET/CT) with whole-body magnetic resonance imaging (wbMRI) in the correct staging of …

Background Determining the stage of non–small-cell lung cancer often requires multiple
preoperative tests and invasive procedures. Whole-body positron-emission tomography …

160 Objectives: The aim of this prospective bi-center trial was to evaluate the diagnostic
accuracy, prognostic potential and cost effectiveness of PET/CT for staging NSCLC …

Background The clinical stage of non-small cell lung cancer (NSCLC) determines the initial
treatment, whereas the pathologic stage best determines prognosis and the need for …